Compare GILT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | CMPX |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 926.7M |
| IPO Year | 1997 | 2020 |
| Metric | GILT | CMPX |
|---|---|---|
| Price | $17.23 | $5.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $20.00 | $14.43 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $850,000.00 |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $11.41 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.30 | $1.33 |
| 52 Week High | $20.38 | $6.88 |
| Indicator | GILT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 40.19 |
| Support Level | $13.11 | $4.78 |
| Resistance Level | $20.38 | $5.86 |
| Average True Range (ATR) | 0.98 | 0.31 |
| MACD | 0.10 | -0.12 |
| Stochastic Oscillator | 98.66 | 23.34 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.